¿Existe estabilidad LDL entre dos dosis en pacientes que usan iPCSK9?

  1. Miguel Ángel López Zúñiga
  2. Miriam Auxiliadora Martín Toro
  3. María de Damas Medina
Revista:
Actualidad médica

ISSN: 0365-7965

Any de publicació: 2019

Tom: 104

Número: 807

Pàgines: 98-102

Tipus: Article

DOI: 10.15568/AM.2019.807.OR04 DIALNET GOOGLE SCHOLAR lock_openDIGIBUG editor

Altres publicacions en: Actualidad médica

Resum

IPCSK9 have been shown to reduce plasma LDL-C levels more than 50%. However, the stability of LDL levels in the interdose period raises questions. We analyze if the reduction of LDL-C is stable during this period. Material and methods: Retrospective descriptive study. All patients, of a tertiary hospital, treated with iPCSK9 were included. Patients were grouped according to the date of the analytical control respect the last dose received, on days 0-3, 4-6, 7-9, 10-12 and 13-15 after the inyection. Results: We included 71 patients with a LDL-C reduction of 55.02% (p <0.001). In those who performed analytical control in the first 3 days reduced 56.83% (p = 0.003), reaching 75.48% between days 4-6 (p <0.001), decreasing to 52.14% between 7-9 days (p <0.001), reaching 32.94% (p = 0.021) from day 13. Conclusions: In our cohort we have observed that the effectiveness of iPCSK9 is not stable during the interdose period, but prospective studies with mayor number of blood extractions would be required to be able to affirm this condition and its real clinical impact

Referències bibliogràfiques

  • Millán J, Alegría E, Guijarro C, Lozano JV, Vitale GC, González Timón B et al. Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian. Med Clin (Barc). 2013; 141(10):430-6.
  • Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1500-9.
  • Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1489-99.
  • Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376(18):1713-1722.
  • Kohli M, Patel K, MacMahon Z, Ramachandran R, Crook MA, Reynolds TM, Wierzbicki AS. Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. Int J Clin Pract. 2017; 71(11).
  • Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol. 2018; 71(1):1-7.
  • Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertasesubtilisin/ kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018; 39(14):1131-1143.
  • Page MM, Watts GF. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular Disease. Diabetes Obes Metab. 2018; 20(2):270-282.
  • Di Bartolo B, Scherer DJ, Brown A, Psaltis PJ, Nicholls SJ. PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. BioDrugs. 2017; 31(3):167-174.
  • Filippatos TD, Kei A, Rizos CV, Elisaf MS. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. J Cardiovasc Pharmacol Ther. 2018; 23(1):3-12.
  • Koren MJ, Roth EM, McKenney JM, Gipe D, Hanotin C, Ferrand AC, et al. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis. Postgrad Med. 2015; 127(2):125-32. doi: 10.1080/00325481.2015.998987. Epub 2015 Jan 22.
  • Endocrinology and metabolic drugs advisory committee (EMDAC) meeting june 10, FDA Briefing Documente. United Sates Food and Drug Administration website. Disponible en: https://www.fda.gov/dvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm450071.htm
Fuente de los datos: Dialnet